Tyme Technologies Inc. (NASDAQ: TYME) is one of today’s hottest stocks, with investors and traders clamouring to find out more.
If you are considering investing in Tyme Technologies stock, this article can help inform your decision. Read on to find out what the company is, what it does, and what the future could hold for it. In addition, find out our price forecast for TYME stock.
If you want to invest in Tyme Technologies immediately, check out the section below. These low-fee platforms are the best places to buy TYME shares right now.
How & where to buy Tyme Technologies shares online
To buy TYME stock quickly and easily, click on one of the links below, fill out some basic information and add funds to your newly-created account. Then, you can choose the number of TYME shares you want and execute your transaction.
Here are the two best platforms to buy, sell and trade Tyme Technologies stock:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Tyme Technologies?
Incorporated in 2011 and based in Bedminster, New Jersey, it is a biotechnology company.
Tyme develops cancer metabolism-based therapies (CMBTs) in North America, and its lead candidate is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer such as lung, breast, pancreatic, prostate, sarcoma, and lymphoma.
The stock price of Tyme is surging on good news. Specifically, the notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. Patent number 11,058,63 crucially includes a targeted delivery of therapeutics to cancer cells.
Should I buy Tyme Technologies stock today?
Investing in biotech companies always carries enhanced risk because products must pass through a lengthy testing process and satisfy all regulatory requirements before achieving commercialisation.
However, the potential for rewards is obvious. So, if you think Tyme Tech is a company that can deliver cancer-combating products to the market, now may be the right time to pull the trigger.
Tyme Technologies price forecast 2021
Our 12-month TYME price target is as follows: $8.